Recursion Co-Founder and CEO, Chris Gibson, Awarded Governor’s Medal for Science and Technology
May 12, 2022
Recursion Co-founder and CEO, Chris Gibson, Ph.D., was honored at the One Utah Summit on May 10, receiving the Governor’s Medal for Science and Technology.
Gov. Spencer Cox presented the award during the summit’s special recognition ceremony. The prestigious award commends the distinguished service, significant achievement, and positive economic impact of individuals to the state of Utah and beyond in the fields of science and technology.
“It’s an incredible honor to receive this award, which speaks to the exciting growth of our life science community and our important role in driving Utah’s economy and healthcare innovation,” said Gibson. “This award is a testament to my colleagues at Recursion and the amazing work they do every day to achieve our mission of radically improving lives, as well as my friends and colleagues across our industry who have contributed to building our innovation ecosystem.”
“On behalf of the entire BioHive community, we congratulate Dr. Chris Gibson on this well-deserved award,” said Kelvyn Cullimore, president and CEO of BioUtah. “As the co-founder and CEO of Recursion, Chris has led the company through exponential growth, beginning with his bold vision to transform drug discovery and better serve patients. As Chairman of the BioHive Board of Directors, he also helps lead an industry effort to brand and expand Utah’s life sciences ecosystem.”
In a statement in advance of the award ceremony, Gov. Cox said, “These awards are going to companies and individuals who are making a lasting impact in our state. On behalf of the state of Utah, I want to congratulate all of the award recipients and wish them the best as they continue to help make Utah a better place.”
The Medal for Science and Technology was one of a larger set of awards announced at the One Utah Summit.
Recent News
- Webinar Recap: Immigration Compliance Under Pressure
- bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
- DGENTHERA AND NUSANO SIGN LETTER OF INTENT FOR ASTATINE‑211 SUPPLY
- 2025 BIO International Recap
- Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation
- Nelson Labs to Double Cleanroom Capacity to Support Growing Demand for Sterility Assurance Services